Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s Amended Patent Law Could Facilitate Compulsory Licenses Of Pharmaceuticals – Patent Attorneys

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Leaders of China's national legislature are currently reviewing amendments to the patent law that could make it easier to force global pharmaceutical firms to license drugs to Chinese competitors in the event of a public health crisis

You may also be interested in...



China Compulsory Licensing Reg Opens Door For Generics Of Patented Drugs

Taking the lead from India’s recent compulsory license for Bayer’s Nexavar, China passes a compulsory license regulation that could allow generics on patented drugs.

China Compulsory Licensing Reg Opens Door For Generics Of Patented Drugs

Taking the lead from India’s recent compulsory license for Bayer’s Nexavar, China passes a compulsory license regulation that could allow generics on patented drugs.

Thailand Could Seek WTO Solution On Compulsory Licensing, Generic Drugs

SHANGHAI - Multinational drug companies and authorities across developed countries have censured Thailand for using compulsory licensing - a method of forcing pharmaceutical outfits holding patents on innovative medicines to allow other companies to turn out the product

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069393

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel